Dallas, Texas – April 19, 2016
Total Clinical Trial Management (TCTM), an emerging full-service CRO based in Dallas, Texas, has delivered Texas-sized results in its most recent difficult-to-enroll, Phase III gastroenterology program. TCTM was created on the founding principle that relationships between research sites and the CRO is a critical element in ensuring successful study completion. TCTM’s proprietary TotalTouch Site Advantage process has proven to dramatically reduce study timelines and deliver results.
The Sponsor and TCTM’s planned enrollment projections were 220 patients within 7 months at 9 research site locations. The target was met 21 weeks ahead of the aggressive timeline in 2 months and 1 week. Due to the outstanding enrollment results, the Sponsor granted TCTM an additional 130 subjects for enrollment with enrollment projections of 130 patients in 5 months across 9 sites. The second target was met 16 weeks ahead of the projected timeline in 6 weeks. For all the projects managed to date by TCTM, the enrollment targets have been met either on time or ahead of schedule.
Total Clinical Trial Management has a wide range of therapeutic expertise with recent areas of focus including pain, orthopedic injury, dermatology, ophthalmology, women’s health, gastrointestinal disease, over-the-counter (OTC), generic and cosmetic studies. Visit our website, www.totalCRO.com to learn more about TCTM and the site-focused model for successful study management.